Google SSO gives you the quickest path into the IIPLA newsroom, your reading access, and member-level continuity across articles. The full login page is still available if you prefer another option.
This report highlights key findings from WIPO’s global study on intellectual property (IP) awareness and perceptions, accompanied by an overview of t…
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
Stayble Therapeutics AB, a Swedish biotechnology company specializing in injectable treatments for chronic back pain, has called an extraordinary general meeting on May 7 to vote on a proposal for voluntary liquidation. The board's recommendation follows unsuccessful efforts to secure partnerships or financing for its…
A recent report from BakerHostetler underscores the urgent need for US businesses to overhaul their intellectual property strategies in response to the transformative effects of artificial intelligence, evolving social media practices, and significant regulatory changes. The firm’s 2026 IP Perspectives report details…
Biotechnology company Moderna has agreed to pay up to $2.25 billion to settle patent litigation over technology used in its COVID-19 vaccine, resolving a dispute with Arbutus Biopharma and Genevant Sciences. The lawsuits alleged that Moderna’s vaccine relied on patented lipid nanoparticle delivery systems, a technolog…
The U.S. Supreme Court concluded its 2023-24 term with significant decisions impacting intellectual property law, including a unanimous ruling on the Lanham Act’s name clause and a split decision on the timing of copyright damages. As the 2024-25 term begins, the Court has agreed to hear additional IP cases while decl…
The year 2024 proved transformative for U.S. intellectual property litigation, marked by steady case volumes, landmark Supreme Court and Federal Circuit decisions, and a surge in disputes involving artificial intelligence and trade secrets. Shifts in venue dynamics, the end of Chevron Deference, and the growing influe…
In a landmark decision, the Federal Circuit has ruled that generic pharmaceutical companies may deduct legal expenses incurred in defending Hatch-Waxman patent litigation as ordinary and necessary business expenses. The ruling, which affirms a lower court's decision in favor of Actavis Laboratories FL, Inc., clarifies…